Unlicensed retatrutide found on UK social media as MHRA seizures mount

Sellers on British social media are offering unlicensed retatrutide, an experimental Eli Lilly injection that no regulator has approved, according to a Sky News investigation broadcast on 7 November 2026. The report comes less than four weeks after the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police seized more than 12,000 fake weight loss pens in Birmingham. The MHRA says any retatrutide sold outside legitimate clinical trials in the UK is supplied illegally. This story sets out what was found, what the trial data do and do not show, and what to watch next.

What the Sky News investigation found online

Sky News reporter Barnaby Papadopulos tracked down social media accounts advertising retatrutide, according to the broadcaster's report as summarised by the UK site fish4news. Some offered what they described as bulk supplies from China. The broadcaster also spoke to a woman in Yorkshire who said she was taken to hospital with a severe allergic reaction after injecting a product she had bought from a seller on Facebook. Her account shows what can go wrong when people inject products from unknown sources, but it has limits. No independent laboratory test of her product has been reported. Nobody can yet say what the injection contained, or whether retatrutide itself, a contaminant or a different substance caused the reaction she described to reporters.

Listings for unlicensed retatrutide often borrow the language of gyms and laboratories, with short codes, fitness slogans and labels such as "research use only". Those words carry no legal weight in Britain. They do not prove what a vial holds, how it was made or that it may lawfully be given to people. Claims of Chinese bulk supply add another layer of doubt, since the US FDA recently put two Chinese GLP 1 ingredient plants on import alert after inspectors reported mould and insects. Lilly describes retatrutide as a triple agonist, because one molecule acts on the GIP, GLP-1 and glucagon receptors. That makes it a different drug from semaglutide and tirzepatide, which UK pharmacies can supply against a valid prescription. Peptide Global is not naming or linking to any seller.

MHRA counterfeit weight loss pens and a year of raids

The Sky News findings follow a run of enforcement actions against fake weight loss medicines across England and Wales. On 14 October 2026, MHRA officers and West Midlands Police raided an industrial unit in Birmingham. The MHRA said the October raid alone took more than 12,000 fake retatrutide and tirzepatide pens out of circulation, along with packaging for about 30,000 more products. The agency put the value of the haul at around £2 million. That count covers both drug names together, and the regulator gave no separate figure for retatrutide. Tim Duffield, who heads intelligence at the MHRA Criminal Enforcement Unit, said in the agency's press release that "Retatrutide has not been authorised for use in the UK."

The MHRA said the October raid alone took more than 12,000 fake retatrutide and tirzepatide pens out of circulation, along with packaging for about 30,000 more products.

Birmingham was not a one off. The MHRA lists three earlier operations against illicit GLP-1 production in about a year, starting with what it called the first such facility found in the UK, in October 2025. In February 2026, North Wales Police made three arrests over suspected illegal sales in Wrexham and Flintshire, citing fraud by false representation, according to the fish4news report. The pattern points to organised packing and distribution, not only individual posts on social media. Our earlier report on the Birmingham warehouse haul looks at the scale of that operation. The table below sets out the actions on record, using the figures each agency gave at the time, without adding estimates of its own.

What the retatrutide Phase 3 trials show

Retatrutide does have real clinical data behind it, gathered under strict trial conditions. Lilly says on its question and answer page, last updated in October 2026, that it has disclosed results from six retatrutide Phase 3 trials. Its trials cover weight, diabetes, sleep apnoea, knee osteoarthritis pain, chronic low back pain, fatty liver disease, and heart and kidney outcomes. In the TRIUMPH-1 obesity trial, published in the New England Journal of Medicine, people in the highest dose group lost 28.3% of their body weight on average after 80 weeks, according to the published results. In TRIUMPH-2, a study of 1,152 adults who had type 2 diabetes alongside obesity or overweight, the top dose group lost 18.8% on average over 80 weeks, against 5.1% on placebo.

Those numbers describe averages in selected trial groups, not what any one person should expect. Trial volunteers received a drug made to a known standard, at set amounts raised in small steps, under regular medical checks. Nausea and diarrhoea were more common on retatrutide than on placebo in TRIUMPH-2. Some dose groups also saw more cases of falling blood pressure and of unusual feelings on the skin, and a share of volunteers quit because of side effects. Researchers are still weighing the overall balance of benefit and harm. None of this data can vouch for unlicensed retatrutide bought online, because there is no way to link such a product to the trial supply. Lilly warns that illicit versions may hold unknown or contaminated ingredients, the wrong amount of active drug, or a different substance altogether.

Legal status and safe access in Britain

The legal position is simple. Lilly states that no regulator anywhere has reviewed or approved retatrutide, and that selling it for human use is unlawful. The MHRA said in a July 2026 public warning that selling retatrutide as a medicine in the UK is illegal, and it repeated in October that products sold as retatrutide outside legitimate clinical trials are supplied illegally. For now, the only lawful route to the drug in Britain is enrolment in an approved trial. People who want help with weight can ask a doctor or pharmacist about licensed GLP-1 medicines, which the MHRA says should come only from a registered pharmacy with a valid prescription. Anyone who suspects a side effect from any medicine can report it through the MHRA Yellow Card scheme.

Several questions remain open. The MHRA release on the Birmingham raid did not report any arrests or charges, and it is not yet known whether the Sky News findings will lead to new cases against sellers. Lilly has not said when it plans to seek approval for retatrutide in Britain, and it says any launch depends on finishing its trials and passing regulatory review. Until then, unlicensed retatrutide remains outside UK medicines law, whatever a listing claims. Concern about unapproved peptides is not unique to Britain. In Australia, a coroner who examined a death linked to unapproved peptides asked the national regulator to consider tighter limits. Readers should watch for MHRA court updates, any platform action against listings and Lilly's regulatory filings.

Conclusion

The Sky News investigation shows that unlicensed retatrutide is still being promoted to UK buyers on social media, despite repeated MHRA raids and a clear legal ban on sale for human use. The trial results are real, but they belong to a supervised research drug, not to products of unknown origin. What happens next depends on enforcement cases, platform responses and Lilly's eventual filings with regulators.